Clinical trials
HIV clinical trials
Below are recruiting hiv clinical trials, each written for real people, not researchers. We’re tracking 583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07438080Recruiting
HPV self-screening vs. doctor screening for anal cancer risk
This trial compares two ways to screen for HPV, a virus linked to anal cancer. People living with HIV will either collect their own sample or have a doctor do it, then switch methods. The goal is to see which is more comfortable and accurate.
Saint-PaulAges 30–65 - NCT07433985Recruiting
California mobile app study for men after jail release
This study tests a mobile app to help men recently released from jail or prison who use drugs or have sex with men stay healthy and avoid HIV. It's for people who don't have HIV and live in certain California counties.
Oakland, CaliforniaAges 18–59 - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT07415811Enrolling by invitation
Spironolactone for HIV-infected adults
This study tests the drug spironolactone, a medicine that helps your body balance fluids and potassium, in both HIV-positive and HIV-negative adults. The goal is to see how it affects a key protein complex in your cells. If you are HIV-positive, you need to have well-controlled HIV with undetectable virus levels and be on stable treatment.
São Paulo, São PauloAges 18–60 - NCT07355413Recruiting
Frailty and health in older adults with HIV in West Africa
This study looks at how frailty (weakness) and other age-related health issues affect older adults living with HIV in West Africa. By comparing those with and without HIV, researchers hope to better understand the care needs of this group.
Bobo-DioulassoAges 60 years+ - NCT06656676Recruiting
WePrEP: HIV prevention tool for transgender women
This study is creating a decision-making tool to help transgender women choose the right PrEP (HIV prevention pill) for them. It is looking for transgender women in Denver who are HIV-negative and interested in learning more about PrEP, as well as healthcare providers who help transgender women decide about PrEP.
Sheridan, ColoradoAges 18–65 - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07349758RecruitingPhase 1
Single dose of two PrEP tablets in healthy volunteers
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
Baltimore, MarylandAges 18 years+ - NCT07335289Recruiting
Same-day HIV prevention shot study
This study tests if starting a new HIV prevention shot (lenacapavir) on the same day you see a doctor and having a say in your follow-up care can help people stick with their prevention routine. It may be an option for you if you are looking for a long-acting HIV prevention method.
Boston, MassachusettsAges 18 years+ - NCT07325500RecruitingPhase 2
Low dose GLP-1 for heart health in HIV
This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.
Houston, TexasAges 18 years+ - NCT06046079Recruiting
HIV Prevention Service Use Study in Washington DC
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT07299500Recruiting
Toxoplasmosis study in non-HIV immune compromised patients
This study looks at toxoplasmosis infections in people with weakened immune systems (not caused by HIV). It aims to learn more about how these infections happen and how they affect patients.
StrasbourgAges 18 years+ - NCT06458504Recruiting
HIV infection and bone marrow health study
This study looks at how HIV infection affects the bone marrow's ability to make blood cells. Researchers will use bone marrow samples already taken from HIV-positive patients and compare them to samples from people without HIV.
Boulogne-BillancourtAges 18 years+ - NCT00404989Recruiting
Pregnancy drug safety registry for people with HIV treatment
This trial is a pregnancy registry that collects information about birth outcomes when certain HIV medicines are taken during pregnancy. It helps detect any major birth defects so future pregnancies can be safer.
Wilmington, North CarolinaAges 12–60 - NCT07246057Recruiting
Improving PrEP access with telehealth and community partners
This study looks at how telehealth can make PrEP (medication that helps prevent HIV) easier to get, by partnering with community organizations in Philadelphia. Researchers want to interview or survey clients and staff to understand what works and what could be improved.
Philadelphia, PennsylvaniaAges 16 years+ - NCT05835479RecruitingPhase 2
Rezafungin to treat Pneumocystis pneumonia in adults with HIV
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
Cape TownAges 18 years+ - NCT07223398Recruiting
Making HIV care decisions with people who've been in the justice system
This trial helps people recently involved with the justice system and who use stimulants or opioids decide on HIV prevention or treatment. It tests a shared decision-making approach for taking HIV medication (ART) or PrEP.
New Haven, ConnecticutAges 18 years+ - NCT07226323Recruiting
WeCare for mental health and medication adherence in South Africa
This trial tests a counselling program called WeCare to help men who have sex with men in Johannesburg stick to their HIV or PrEP medication and manage depression symptoms. It is designed for those who are struggling with adherence or have unsuppressed HIV.
JohannesburgAges 18 years+ - NCT07221123RecruitingPhase 2
Smell and memory training for brain health
This study tests whether smell exercises can improve memory and thinking in people who are worried about their brain health. If you are 40 or older and have mild memory concerns, you may be able to join.
Birmingham, AlabamaAges 40 years+ - NCT05905640Recruiting
PrEP clinic support study for Kenya health workers and policy makers
This trial tests a “one-stop” support pathway meant to make it easier for PrEP clinics in Kenya to deliver PrEP care. It involves interviews with people using PrEP services and with healthcare and policy leaders who help run or guide PrEP delivery.
KisumuAges 15 years+ - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT07199335RecruitingPhase 4
Injectable HIV prevention drug for people who inject drugs
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
Boston, MassachusettsAges 18 years+ - NCT06306196RecruitingPhase 2
Hepatitis E vaccine study in healthy adults, children, and people with HIV
This study tests a hepatitis E vaccine called Hecolin in healthy people (ages 2–45) and in adults (18–45) living with HIV who are on antiviral treatment. It aims to see how well the vaccine works and if it's safe for different groups.
Ga-RankuwaAges 2–45
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv?
- Yes. Clin2 currently lists 583 recruiting hiv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.